Rosuvastatin may not decrease inflammation markers in HIV patients at cardiovascular risk
Researchers have found in a new research that Among virologically suppressed persons with HIV at moderate risk of cardiovascular disease, daily administration of rosuvastatin did not lead to significant reductions in inflammatory markers. The research has been published in the Journal of Infectious Diseases.
Statins may help prevent cardiovascular disease (CVD) in people with HIV (PWH) with chronic inflammation due to their pleotropic lipid lowering and anti-inflammatory properties. Therefore, guidelines recommend that all patients with known CVD (including patients with HIV) should be prescribed high-dose statin therapy if tolerated. For primary prevention of cardiovascular events in patients without known CVD, statins also reduce relative risk of vascular events on the order of 20–40%, but the absolute risk reduction is much lower than for secondary prevention.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd